4.58 -0.735 (-13.83%) | 02-11 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 6.96 | 1-year : | 8.07 |
Resists | First : | 5.96 | Second : | 6.9 |
Pivot price | 5.42 ![]() |
|||
Supports | First : | 4.42 | Second : | 3.68 |
MAs | MA(5) : | 5.67 ![]() |
MA(20) : | 5.25 ![]() |
MA(100) : | 7.45 ![]() |
MA(250) : | 16.87 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 34.6 ![]() |
D(3) : | 52.4 ![]() |
RSI | RSI(14): 37.2 ![]() |
|||
52-week | High : | 36.25 | Low : | 4.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FDMT ] has closed above bottom band by 15.7%. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 5.27 - 5.31 | 5.31 - 5.33 |
Low: | 4.5 - 4.54 | 4.54 - 4.56 |
Close: | 4.53 - 4.59 | 4.59 - 4.62 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Mon, 10 Feb 2025
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
Mon, 10 Feb 2025
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts - Benzinga
Tue, 21 Jan 2025
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT - PR Newswire
Mon, 13 Jan 2025
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 4.623e+007 (%) |
Held by Institutions | 2.528e+007 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | -9.708e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -2.85 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 704 % |
Return on Equity (ttm) | 400 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -34.97 |
Sales Per Share | -8.6 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.6369e+008 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | -1.61 |
Price to Sales | -0.54 |
Price to Cash Flow | 0 |
Dividend | 7.67e+006 |
Forward Dividend | 8.92e+006 |
Dividend Yield | 167467000% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |